Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant;Remisión molecular de una leucemia mieloide crónica en un paciente con segundo trasplante renal y hepatitis

Nefrologia

Volumn 29, Issue 6, 2009, Pages 604-607

  Castillo Rama, M ^a   Paz Artal, E ^a   Grande, C ^a   Martinez Sanchez P ^a   Morales, José María ^a   Andres A ^a   Olavarria, E ^b   Marin D ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Chronic myeloid leukemia; Renal transplant

Indexed keywords

ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; HEPATITIS C; HUMAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; REMISSION; REOPERATION;

HEPATITIS C; HUMANS; KIDNEY TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; REMISSION INDUCTION; REOPERATION;

EID: 75349092700     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.2009.29.6.5346.en.full     Document Type: Article

References (16)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7.
2. Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 1961;27:1013-35.
3. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243(5405):290-3.
4. Koca E, Cetiner D, Goker H, Aksu S, Ozcebe OI, Haznedaroglu IC, et al. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation Clin Nephrol 2005;64(4):324-6.
5. Thierry A, Dreyfus B, Bridoux F, Abou Ayache R, Milin S, Guilhot F, et al. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation. Nephrol Dial Transplant 2007;22(6):1791-2.
6. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-17.
7. Appel S, Balabanov S, Brümmendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005;23(8):1082-8.
8. Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol 2005;83(1):48-56.
9. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004;104(4):1094-9.
10. Kitiyakara C, Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 2002;17(4):685-7.
11. Pou M, Saval N, Vera M, Saurina A, Solé M, Cervantes F, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003;44(7):1239-41.
12. Chen L, Wang JM, Xu XP Gao L, Fei XH, Lou JW, et al. The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi (Abstract) 2003;11(6):600-3.
13. Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007;13(48):6608-11.
14. Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006;81(3):189-92.
15. Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology 2007;12(1):49-53.
16. Morales JM, Campistol JM.Transplantation in the Patient with Hepatitis C. J Am Soc Nephrol 2000;11:1343-53.